The Israeli Ministry of Economy and Industry and the Israel Innovation Authority have funded over NIS 25 million ($6.9 million) in grants to innovative medical technology companies. RenalSense is one of the three medical companies that were awarded.

“As part of our overall strategy, the field of biomedicine is at the top of our priorities, with the potential of becoming Israel’s next growth engine. Alongside the flourishing field of information technology, we set a goal of developing our life sciences, based on of Israel’s world-leading scientific accomplishments and technological strengths,” said Dr. Ami Applebaum, the Chief Scientist of the Israeli Ministry of Economy and Industry and chairman of the Israel Innovation Authority.

Avi Kleiman, CEO of RenalSense, said: “Thanks to previous support of the Innovation Authority,RenalSense  has brought to market a unique system for automatic continuous monitoring of kidney function in critical care. RenalSense‘s first product provides early indications of changes in kidney function by monitoring urine flow in real time. The current grant supports the development of second generation sensors to detect additional real-time parameters and will provide clinicians additional indications regarding vital signs related to kidney function (such as heart, lungs, vascular diseases, sepsis). This will significantly improve clinician’s ability to identify the source of Acute Kidney Injury (AKI) and to deliver targeted treatments on time. ”

Based in hi-tech center of Har Hozvim in Jerusalem, RenalSense provides real-time kidney function monitoring which is important for patients in intensive care units (ICU).

A report on Urinal Biomarkers was released by Insight.  RenalSense was identified as one of the key players along with companies such as  Abbott, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc.